Exhibit 99.1
Autolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day
Program and webcast – today, March 26, 2019 at 8:00 am ET
LONDON, UK, March 26, 2019 — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next generation programmed T cell therapies for the treatment of cancer, plans to present insights into the science behind tumor defense mechanisms and the company’s novel programmed T cell therapy programs in development utilizing targeted, modular approaches designed to address these mechanisms at its inaugural R&D Day, today, in New York. In addition, the company plans to provide an update on its AUTO3 program in pediatric acute lymphocytic leukemia (pALL).
AUTO3 is the first dual-targeting CD19 and CD22 programmed T cell therapy in development for both pALL and relapsed or refractory diffuse largeB-cell lymphoma (DLBCL). Updated data from the ongoing AMELIA Phase 1/2 study in pALL demonstrates that 6 out of 6 (100%) patients treated at the highest dose (³3 x106/kg) achieved minimal residual disease (MRD) negative complete responses (CR). Ongoing MRD negative CR remissions were noted in 4 out of 6 (67%) patients, with duration of up to 10 months as of February 2019, the date of latest datafollow-up. There have been no reported CD19 or CD22 negative relapses in CAR T naïve patients. Data also showed that AUTO3 continues to be generally well tolerated with no³ Grade 3 CRS, no ICU admission, and no pressors or critical care support for CRS required. The Phase 2 portion of the study is expected to start in the second half of 2019. For more information about this trial and the inclusion criteria, visit www.ClinicalTrials.gov (NCT03289455).
“We are pleased to be hosting our inaugural R&D day, providing a unique opportunity to present anin-depth overview of our differentiated technology, multiple programs, market opportunities and the significant pipeline progress we have achieved, to date,” stated Dr. Christian Itin, chairman and chief executive officer of Autolus. “We expect to report data on all of our active clinical programs at key medical conferences during 2019. Additionally, over the coming months, we expect to move two programs into registrational trials and to progress our next generation programs toward the clinic.”
Today’s R&D program will include the following presentations:
| | • | | Dr. Christian Itin, Chairman and Chief Executive Officer of Autolus –Welcome and Overview |
| | • | | Dr. Samir N. Khleif, Director of the Loop Immuno-Oncology Lab and Biomedical Scholar and Professor of Oncology, Georgetown University Medical Center - Immunotherapy, A Combinatorial Approach for Success |
| | • | | Dr. MuhammadAl-Hajj, Senior Vice President, Translational Sciences of Autolus –Translational Aspects of Tumor Heterogeneity |
| | • | | Dr. Martin Pule, Chief Scientific Officer and Founder of Autolus and Clinical Senior Lecturer at University College London Cancer Institute –Tackling Solid Tumors: A Modular Approach to T Cell Programming |
| | • | | Dr. Vijay Peddareddigari, Chief Medical Officer of Autolus –Clinical Update: Current and Next Generation Programs |
